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SYMPOSIUM - THE IMPORTANT THING IS NOT TO STOP QUESTIONING
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Abstract Oral contraceptive-induced menstrual migraine
(OCMM) is a particularly severe form of migraine trig-
gered by the cyclic hormone withdrawal. To review the
efficacy of frovatriptan vs. other triptans, in the acute
treatment of OCMM through a pooled analysis of three
individual randomized Italian studies. With or without aura
migraineurs were randomized to frovatriptan 2.5 mg or
rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmi-
triptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan
12.5 mg (study 3). All studies had a multicenter, random-
ized, double-blind, crossover design. After treating 1–3
episodes of migraine in 3 months with the first treatment,
patients switched to the other treatment for the next
3 months. In this analysis, the subset of 35 of the 280
women of the intention-to-treat population taking com-
bined oral contraceptives and experiencing a migraine
attack during the withdrawal phase, were analyzed. The
proportion of pain free and pain relief at 2 h were 25 and
51 % with frovatriptan and 28 and 48 % with comparators
(p = NS). At 24 h, 71 and 83 % of frovatriptan-treated
patients and 60 and 76 % of comparator-treated patients
were pain free (p \ 0.05 between treatments) and had pain
relief (p = NS), respectively. Relapse at 24 and 48 h was
significantly (p \ 0.05) lower with frovatriptan (17 and
21 %) than with the comparators (27 and 31 %). Our
results suggest that, due to its sustained antimigraine effect,
frovatriptan may be particularly suitable for the manage-
ment of OCMM than other triptans.
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Introduction
Oral contraceptive-induced menstrual migraine (OCMM)
is a menstrual migraine subtype mainly caused by estrogen
withdrawal occurring during the week of pill suspension [1,
2]. OCMM is a poorly studied, but particularly severe and
disabling form of menstrual migraine [3]; it is codified by
the ICHDII classification as estrogen-withdrawal headache
(code 8.4.3) [2].
Evidence-based guidelines recommend treating moder-
ate or severe migraine, including menstrual migraine, with
migraine-specific agents [4]. Among these, triptans are
considered to provide a greater clinical benefit and a more
favorable adverse event profile than other anti-migraine
drugs [4].
Frovatriptan is a second-generation triptan, with a dis-
tinct pharmacokinetic profile. Its high selectivity for the
cerebral vasculature, long elimination half life and high
persistence of therapeutic action may be useful in pre-
venting menstrual migraine, but also for treating acute
attacks, as shown by several randomized trials [4–7].
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Although frovatriptan is currently among the triptans rec-
ommended for prevention of menstrual migraine [8–10], its
efficacy in OCMM has had limited investigation [11]. In
the present retrospective analysis, we report on a pooled
individual data analysis of three randomized double-blind
studies [12–14] performed to verify whether frovatriptan
may be effective in the acute management of an OCMM
attack and whether its efficacy may differ from that of other
triptans.
Methods
Study population and design
Information on the study design for the three original
studies is reported in the main publications [12–14]. In
brief, the studies recruited subjects of both genders, aged
18–65 years, with a current history of migraine with or
without aura, according to the International Headache
Society definition [2], and with at least one, but no more
than six migraine attacks per month for 6 months prior to
entering the study. In the present retrospective analysis,
only the group of women with OCMM was taken into
consideration. OCMM was defined according to IHS cri-
teria, as an estrogen-withdrawal headache, namely a
migraine without aura developing within 5 days after ces-
sation of estrogen use and resolving within 3 days [2].
Estrogen use must have lasted for at least 3 weeks prior to
cessation. Patients taking all types of combined oral con-
traceptives, except those entailing a withdrawal period of
less than 5 days, were considered eligible for inclusion in
the present retrospective analysis.
The studies had a multicenter, randomized, double
blind, cross-over design. A total of 33 different Italian
centers were involved in the studies. Each patient received
frovatriptan 2.5 mg or rizatriptan 10 mg in the first study
[12], frovatriptan 2.5 mg or zolmitriptan 2.5 mg in the
second study [13], and frovatriptan 2.5 mg or almotriptan
12.5 mg in the third study [14], in a randomized sequence.
After treating 1–3 episodes of migraine in no more than
3 months with the first treatment, the patient switched to
the other treatment and was asked to treat a maximum of
three episodes of migraine in no more than 3 months with
the second treatment.
The study design foresaw three visits and each patient’s
participation time in the study had not to exceed 6 months
from randomization. Subjects having no migraine episodes
during one of the two observation periods were excluded
from the study.
Randomization was done by blocks of four. Blindness
ensured by the overencapsulation technique, i.e., by
inserting study drug tablets in capsules.
Data analysis
The present pooled analysis was carried out in all women
with OCMM, who treated at least one episode of OCMM
with both medications in each study.
The following endpoints were evaluated: (a) the pro-
portion of pain-free episodes at 2 and 24 h (absence of
migraine episodes 2 and 24 h after intake of one dose of
study drug); (b) the proportion of pain-relief episodes at 2
and 24 h (a decrease in migraine intensity from severe or
moderate to mild or none 2 and 24 h after the intake of one
study drug dose); (c) relapse within 24 and 48 h (defined as
an episode of migraine occurring within 24 and 48 h from
the previous episode, after a period without migraine).
Continuous variables were summarized by computing
average values and standard deviations (SD), while cate-
gorical variables by computing the absolute value and the
frequency (as percentage). Study endpoints were compared
between groups by a Student’s t test (continuous variables)
or by a v2 test (categorical variables). The level of statis-
tical significance was kept at 0.05 for all analyses.
Results
The main study population consisted of 346 subjects, of
which 280 (81 %) were women and 224 were in the fertile
Fig. 1 Flow diagram of the patients throughout the study
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age. A total of 35 out of the 224 eligible women (16 %)
were taking oral contraceptives, treated at least one episode
of OCMM with both medications and were thus included in
the present analysis. A flow diagram of participants
throughout the study is summarized in Fig. 1.
Demographic and clinical baseline data of the 35 women
with OCMM attacks and of the 189 women with non-
OCMM attacks are reported in Table 1. No statistically
significant differences were observed between the two
subgroups of women for any of the explored variables.
A total of 144 out of the overall 1,289 attacks occurring
in the 224 women in fertile age were classified as OCMM:
73 of the 144 attacks (51 %) were treated with frovatriptan
and 71 (49 %) with comparators (8 women treated with
rizatriptan, 12 with zolmitriptan and 15 with almotriptan).
As shown in Fig. 2, the proportion of pain free and pain-
relief episodes at 2 h were not significantly (p = NS) dif-
ferent between frovatriptan (25 and 51 %) and the
comparators (28 and 48 %, respectively). At 24 h, a larger
proportion of women treated with frovatriptan were pain
free (71 vs. 60 % comparators, p \ 0.05) and had pain
relief (83 vs. 76 % comparators, p = NS).
Finally, the rate of relapses at 24 and 48 h was signifi-
cantly (p \ 0.05) lower with frovatriptan (17 and 21 %)
than with the comparators (27 and 31 %) (Fig. 2).
Discussion
As shown in numerous randomized trials, frovatriptan
represents a well known and effective option for acute [4–
6, 11] or prophylactic treatment [15–17] of menstrual
migraine. The present study, based on a pooled analysis of
three double-blind, randomized, direct comparative, cross-
over studies [12–14], demonstrates that frovatriptan is
clinically effective also for the acute treatment of OCMM,
a particular menstrual migraine subtype.
According to our results, the clinical efficacy of frova-
triptan at 2 h was similar to that of the other triptans, with
the overall pain-free rates of approximately 25 % and of
pain-relief rates of approximately 50 %. As expected, such
proportions progressively increased during the period of
observation, reaching larger values at 24 h under frova-
triptan. In particular, this drug showed a more sustained
relieving effect on migraine than the other triptans, with
lower headache relapses after 24 h and even more so after
48 h and such findings might be explained by differences
in the pharmacokinetics of frovatriptan when compared
with the other triptans [7, 18].
Very poor evidence is available on the efficacy of trip-
tans in OCMM and no previous direct comparison studies
of various triptans have ever been published. In a pilot,
open label, uncontrolled study, 20 women treating an
OCMM acute attack with frovatriptan 2.5 mg displayed
pain-free and pain-relief rates of 10 and 55 % at 2 h, and of
Table 1 Baseline demographic and clinical data of the 35 women with oral contraceptive-induced menstrual migraine (OCMM) and of the 189






Age (years, mean ± SD) 35 ± 9 34 ± 7 NS
Height (cm, mean ± SD) 163 ± 5 164 ± 6 NS
Weight (kg, mean ± SD) 59 ± 10 59 ± 10 NS
Age at onset of migraine (years, mean ± SD) 18 ± 7 16 ± 6 NS
Migraine attack duration [2 days (n, %) 7 (20) 45 (24) NS
MIDAS score (mean ± SD) 22 ± 20 23 ± 15 NS
No use of triptans in the previous 3 months (n, %) 16 (46) 79 (42) NS
Migraine attacks with aura (n, %) 4 (10) 29 (10) NS
Data are shown as mean (±SD), or absolute (n) and relative frequency (%). p value refers to the statistical significance of the between-group
difference
Fig. 2 Main study endpoints in the group of women with oral
contraceptive-induced menstrual migraine (OCMM) treated with
frovatriptan (open bars) and the comparators (grey bars). Data are
reported as relative (%) frequencies for pain free (PF) at 2 and 24 h,
for pain relief (PR) at 2 and 24 h, and for relapses at 24 and 48 h. The
p values on top of the bars refer to the level of the statistical
significance of the difference between the two study drugs
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60 and 75 % at 24 h [11]. Migraine relapsed within 24 h in
36 % of patients [11]. In a cross-over, randomized study,
46 % of the women taking 50 mg of oral sumatriptan
achieved pain relief at 2 h and 18 % were pain free, with
almost comparable results observed with the suppository
formulation of sumatriptan [19].
An additional interesting finding of our retrospective
analysis is that immediate and delayed efficacy of frova-
triptan in the subgroup of OCMM is superimposable to that
previously observed in the whole subgroup of women with
menstrual migraine [6].
Despite the interesting results, we must recognize the
limitation of the post hoc nature of our analysis. However,
to our knowledge, no comparative prospective studies of
triptans in OCMM are yet available or have been planned.
Our results might be helpful to stimulate the design and
implementation of larger direct comparative randomized
clinical trials evaluating triptan efficacy in such a specific
subtype of menstrual migraine.
In conclusion, our analysis of individual data of double-
blind, randomized, cross-over trials, suggests that frova-
triptan and other widely employed triptans share a similar
efficacy in the immediate treatment of acute attack of
OCMM. However, frovatriptan due to its sustained an-
timigraine effect, may be more suitable for the manage-
ment of OCMM than other triptans.
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